World Journal of Endocrine Surgery

Register      Login

VOLUME 15 , ISSUE 3 ( September-December, 2023 ) > List of Articles

Original Article

Anaplastic Thyroid Carcinoma: A 20-year Institutional Review

Keat How Teoh, Imisairi Ab Hadi

Keywords : Anaplastic thyroid cancer, Cancer, Endocrine, Surgery, Thyroid, Thyroid cancer

Citation Information : Teoh KH, Hadi IA. Anaplastic Thyroid Carcinoma: A 20-year Institutional Review. World J Endoc Surg 2023; 15 (3):67-70.

DOI: 10.5005/jp-journals-10002-1463

License: CC BY-NC 4.0

Published Online: 20-04-2024

Copyright Statement:  Copyright © 2023; The Author(s).


Background: Anaplastic thyroid cancers (ATC) are highly aggressive and lethal. Despite their low incidence, they account for a significant portion of thyroid cancer-related deaths. In this review, we will examine the clinical characteristics of ATC patients at our center over the past 20 years and their prognosis. Materials and methods: We retrospectively reviewed all ATCs diagnosed at Hospital Raja Perempuan Zainab II, Kota Bharu, Malaysia, from 2004 to 2023. Patients were identified from our lab database, and their clinical details were obtained from their medical records. Results: There were 42 patients, with a female-to-male ratio of 1.6:1 and a median age of 62 years. The majority (92.6%) presented with goiter larger than 4 cm and were female (61.9%). Only one patient had a history of differentiated thyroid cancer (DTC). Most patients (76.2%) presented with goiters lasting <10 years, while only 10 patients had a history lasting for >10 years. Hyperthyroidism was observed in only nine cases, while the rest were euthyroid. Common presenting complaints included dysphagia (59.5%), dyspnea (59.5%), and hoarseness of voice (57%). A large portion of the patients presented with advanced disease, with 26 patients showing distant metastasis, 28 patients exhibiting extrathyroidal extension, and 23 patients having lymph node involvement. The majority (66.7%) survive <3 months from the time of diagnosis. Conclusion: The management of ATC has evolved from palliative care to personalized therapies. However, the prognosis still remains grim. Further research and clinical trials are needed to optimize treatment strategies to improve quality of life and overall survival (OS).

PDF Share
  1. Jannin A, Escande A, Al Ghuzlan A, et al. Anaplastic thyroid carcinoma: an update. Cancers 2022;14(4):1061. DOI: 10.3390/cancers14041061
  2. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006;13(4):453–464. DOI: 10.1245/ASO.2006.05.042
  3. Bible KC, Kebebew E, Brierley J, et al. 2021 American Thyroid Association Guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2021;31(3):337–386. DOI: 10.1089/thy.2020.0944
  4. Janz TA, Neskey DM, Nguyen SA, et al. Is the incidence of anaplastic thyroid cancer increasing: a population based epidemiology study. World J Otorhinol Head Neck Surg 2019;5(1):34–40. DOI: 10.1016/j.wjorl.2018.05.006
  5. Lin B, Ma H, Ma M, et al. The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis. Am J Translat Res 2019;11(9):5888–5896. PMID: 31632557.
  6. Ng SH. The aggressive anaplastic thyroid carcinoma: a case report and institutional review. World J Endocr Surg 2012;4:1–3. DOI: 10.5005/jp-journals-10002-1087
  7. McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001;130(6):1028–1034. DOI: 10.1067/msy.2001.118266
  8. Xu B, Fuchs T, Dogan S, et al. Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases. Thyroid 2020;30(10):1505–1517. DOI: 10.1089/thy.2020.0086
  9. Nachalon Y, Stern-Shavit S, Bachar G, et al. Aggressive palliation and survival in anaplastic thyroid carcinoma. JAMA Otolaryngol Head Neck Surg 2015;141(12):1128–1132. DOI: 10.1001/jamaoto.2015.2332
  10. Haddad RI, Bischoff L, Ball D, et al. Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2022;20(8):925–951. DOI: 10.6004/jnccn.2022.0040
  11. Ain KB. Anaplastic thyroid carcinoma: a therapeutic challenge. Seminars in surgical oncology 1999;16(1):64–69. DOI: 10.1002/(sici)1098-2388(199901/02)16:1<64::aid-ssu10>;2-u
  12. Nagaiah G, Hossain A, Mooney CJ, et al. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol 2011;2011:542358. DOI: 10.1155/2011/542358
  13. Us-Krasovec M, Golouh R, Auersperg M, et al. Anaplastic thyroid carcinoma in fine needle aspirates. Acta Cytol 1996;40(5):953–958. DOI: 10.1159/000334007
  14. Poisson T, Deandreis D, Leboulleux S, et al. 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Molecul Imag 2010;37(12):2277–2285. DOI: 10.1007/s00259-010-1570-6
  15. Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol 2010;22(6):486–497. DOI: 10.1016/j.clon.2010.03.013
  16. Lo CY, Lam KY, Wan KY. Anaplastic carcinoma of the thyroid. Am J Surg 1999;177(4):337–339. DOI: 10.1016/s0002-9610(99)00052-5
  17. Hu S, Helman SN, Hanly E, et al. The role of surgery in anaplastic thyroid cancer: a systematic review. Am J Otolaryngol 2017;38(3):337–350. DOI: 10.1016/j.amjoto.2017.02.005
  18. Rao SN, Zafereo M, Dadu R, et al. Patterns of treatment failure in anaplastic thyroid carcinoma. Thyroid 2017;27(5):672–681. DOI: 10.1089/thy.2016.0395
  19. Maniakas A, Dadu R, Busaidy NL, et al. Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019. JAMA Oncol 2020;6(9):1397–1404. DOI: 10.1001/jamaoncol.2020.3362
  20. Pezzi TA, Mohamed ASR, Sheu T, et al. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: outcomes from the national cancer data base. Cancer 2017;123(9):1653–1661. DOI: 10.1002/cncr.30493
  21. Brierley J, Sherman E. The role of external beam radiation and targeted therapy in thyroid cancer. Sem Radiat Oncol 2012;22(3):254–262. DOI: 10.1016/j.semradonc.2012.03.010
  22. Chen J, Tward JD, Shrieve DC, et al. Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983–2002. Am J Clin Oncol 2008;31(5):460–464. DOI: 10.1097/COC.0b013e31816a61f3
  23. Zhou W, Yue Y, Zhang X. Radiotherapy plus chemotherapy leads to prolonged survival in patients with anaplastic thyroid cancer compared with radiotherapy alone regardless of surgical resection and distant metastasis: a retrospective population study. Front Endocrinol 2021;12:748023. DOI: 10.3389/fendo.2021.748023
  24. Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol 2022;33(4):406–415. DOI: 10.1016/j.annonc.2021.12.014
  25. Wang JR, Zafereo ME, Dadu R, et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF(V600E)—mutated anaplastic thyroid carcinoma. Thyroid 2019;29(8):1036–1043. DOI: 10.1089/thy.2019.0133
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.